LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Companyโs lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
์ข
๋ชฉ ์ฝ๋ LENZ
ํ์ฌ ์ด๋ฆLENZ Therapeutics Inc
์์ฅ์ผJun 25, 2021
CEOSchimmelpennink (Evert)
์ง์ ์42
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 25
์ฃผ์- -
๋์- -
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ- -
์ฐํธ ๋ฒํธ- -
์ ํ- -
์น์ฌ์ดํธ- -
์ข
๋ชฉ ์ฝ๋ LENZ
์์ฅ์ผJun 25, 2021
CEOSchimmelpennink (Evert)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์